This will play a video - An illustration of the RDN Procedure

WHAT IS RDN?

Get an overview of the Medtronic Renal Denervation Procedure.

A DIFFERENT APPROACH TO HYPERTENSION

The Medtronic Renal Denervation (RDN) procedure (also known as the Blood Pressure Procedure) delivers energy to the nerves leading to the kidneys that help regulate blood pressure. This minimally invasive method may help achieve a sustained reduction in blood pressure. Data from the SPYRAL HTN-ON MED study suggests RDN also offers the opportunity to reduce blood pressure independent of patient medication adherence.¹

A PROCEDURE, NOT A PILL

Renal denervation offers a different way to improve your patients’ hypertension that works with lifestyle changes, and is not dependent on medication adherence.

  • A procedure, not a daily pill
  • Complementary to existing therapies 
  • Results are independent of current drug regimen1,2
  • Works independently of patient adherence, 24-hours a day1

KIDNEYS ARE KEY

Kidneys are part of the body's blood pressure control mechanism. Overactivity of the nerves that travel to the kidneys can cause high blood pressure.³ These nerves can be ablated to help the kidneys better manage blood pressure.⁴ The Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter positions electrodes to generate 360 degrees of ablation in the renal artery.

RDN SPYRAL In Situ

PATIENT SELECTION

Who is a candidate for RDN?

LEARN MORE

Test Your HTN IQ

See how much you know about the prevalence and risks of hypertension.

Take The Quiz
Patient Getting Blood Pressure Measured

LET'S FIGHT A GLOBAL HEALTHCARE CRISIS

Access support resources for getting started with RDN. 

CONTACT US
1

Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-2355.

2

Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–2170.

3

Black HR, Elliot W. Hypertension: A companion to Braunwald's Heart Disease. 2nd ed. 2012.

4

Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009 Dec;54(6):1195-201.

All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan or France.